Skip to main content
. 2015 Apr 22;79(5):695–708. doi: 10.1111/bcp.12545

Figure 2.

Figure 2

Effect of QVA149, its monocomponents and tiotropium (A) and UMEC/VI and its monocomponent (B) on mean TDI focal score at week 26. (A) SHINE trial data; (B) studies 373 and 361 data. *P < 0.001 for comparisons with placebo; †P = 0.007 for comparison with tiotropium; ‡P = 0.017 for comparison with placebo. The horizontal lines are the comparisons of QVA149 with indacaterol, glycopyrronium and tiotropium in (A) and of UMEC/VI with UMEC and VI alone in (B)